Slingshot members are tracking this event:

Data from Novartis' (NVS) RTH258 (brolucizumab) Phase 3 study in nAMD patients released

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks
NVS Community voting in process
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jun 20, 2017
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Phase 3, Neovascular Amd, Rth258, Brolucizumab